USPTO Art Unit 1671 Prosecution Statistics

Art Unit Information

Art Unit: 1671
Group: 1670
Tech Center: 1600
Total Cases: 8,817
Last Active: October 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19350804LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAYOctober 2025January 2026Allow310NoNo
19350928LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAYOctober 2025January 2026Allow310NoNo
19294594VARIANT STRAIN-BASED CORONAVIRUS VACCINESAugust 2025March 2026Allow711YesNo
19282553PLANT COLONIZATION ASSAYS USING NATURAL MICROBIAL BARCODESJuly 2025March 2026Allow810NoNo
19262172RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOFJuly 2025August 2025Allow200YesNo
19246586FUSION ANTIGEN OF PORCINE GETAH VIRUS, KIT, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFJune 2025December 2025Allow610NoNo
19204075NUCLEIC ACID MOLECULES AND USES THEREOFMay 2025August 2025Allow310NoNo
19203759SYSTEM FOR PRODUCING AND DELIVERING CONTACTLESS VETERINARY PASSIVE IMMUNIZATIONMay 2025November 2025Allow611NoNo
19183257SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINESApril 2025November 2025Allow710YesNo
19092603COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMarch 2025January 2026Allow1020NoNo
19091651Methods of Detecting, Identifying and Quantifying Wild Spike Protein and Covid Vaccine Spike ProteinsMarch 2025November 2025Allow820NoNo
19077147ANTIBIOTIC FREE TREATMENT OF MASTITISMarch 2025August 2025Allow510YesNo
19067863Phage Composition and Its Use in Strengthening Soil Carbon FixationMarch 2025October 2025Allow710NoNo
19053784Mutated Glycoprotein of Vesicular Stomatitis VirusFebruary 2025July 2025Allow510NoNo
19053808Mutated Glycoprotein of Vesicular Stomatitis VirusFebruary 2025July 2025Allow510NoNo
19052822ADENO-ASSOCIATED VIRUS VARIANTFebruary 2025August 2025Allow611NoNo
19046064SURFACE-MODIFIED VIRAL PARTICLES AND MODULAR VIRAL PARTICLESFebruary 2025September 2025Allow720NoNo
19022291T-Cell Modulatory Multimeric Polypeptides and Methods of Use ThereofJanuary 2025May 2025Allow400NoNo
19022712INFLUENZA VACCINEJanuary 2025May 2025Allow400NoNo
19017356MUTANTS OF RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEINSJanuary 2025May 2025Allow410YesNo
19014949LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAYJanuary 2025July 2025Allow610NoNo
19012978VIRAL VECTOR DELIVERY SYSTEM FOR BOTH RESPIRATORY AND DIGESTIVE TRACTS OF PIGS AND APPLICATION THEREOFJanuary 2025June 2025Allow510YesNo
19007447METHODS OF TARGETED DELIVERY TO A HOST USING A CARRIERDecember 2024May 2025Allow500NoNo
19000472BETACORONA VIRUS mRNA VACCINESDecember 2024June 2025Allow620YesNo
18965925NANOBODY TARGETING INFLUENZA A VIRUS NUCLEOPROTEIN AND APPLICATION THEREOF, AND NUCLEIC ACID ENCODING NANOBODYDecember 2024August 2025Allow920YesNo
18964018Alpha-herpesvirus Insensitive Monoclonal Cell Strain, and Preparation Method Therefor and Use ThereofNovember 2024April 2025Allow411NoNo
18955940PREPARATION METHOD AND APPLICATION OF NANOBODY TARGETING DENGUE VIRUS NS1 PROTEINNovember 2024April 2025Allow510NoNo
18865515FUSION PROTEIN AND USE THEREOFNovember 2024March 2025Allow400NoNo
18941809NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUSNovember 2024May 2025Allow611YesNo
18940501ARTIFICIAL RNA MOLECULES ENCODING A NOROVIRUS ANTIGEN AND USES THEREOFNovember 2024September 2025Allow1010NoNo
18936852METHODS OF FABRICATING CARRIERS FOR TARGETED DELIVERY TO A HOSTNovember 2024April 2025Allow510NoNo
18915537ENGINEERED MUSCLE TARGETING COMPOSITIONSOctober 2024May 2025Allow701NoNo
18903289METHOD FOR CONSTRUCTING gE PROTEIN-DELETED PSEUDORABIES VIRUS STRAIN USING ADENINE BASE EDITOR AND USE THEREOFOctober 2024April 2025Allow710NoNo
18895059PRE-FUSION RSV F ANTIGENSSeptember 2024February 2026Abandon1720NoNo
18891555MULTIPLEX CELLULAR ASSAYS FOR SCREENING AND QUALITY ASSESSMENT OF ENGINEERED CELLSSeptember 2024December 2025Abandon1511NoNo
18812721RAPID DETECTION OF KNOWN AND EMERGING INFLUENZA VIRUSESAugust 2024July 2025Abandon1131NoNo
18804734RECOMBINANT VIRUS, COMPOSITION COMPRISING THE SAME, AND USES THEREOFAugust 2024December 2025Allow1621YesNo
18801895ESTABLISHMENT AND SUSPENSION ACCLIMATION OF CRFK ADHERENT CELL LINE, AND ITS APPLICATIONAugust 2024January 2025Allow510NoNo
18801071NUCLEIC ACID VACCINESAugust 2024June 2025Abandon1010YesNo
18800440RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINEAugust 2024December 2024Allow410NoNo
18801143NUCLEIC ACID VACCINESAugust 2024January 2025Allow510NoNo
18801174NUCLEIC ACID VACCINESAugust 2024March 2025Allow710NoNo
18798779RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATIONAugust 2024May 2025Allow910NoNo
18792611COXSACKIEVIRUS B4 STRAIN AND APPLICATION THEREOFAugust 2024May 2025Abandon1010NoNo
18790657CAPSID VARIANTS AND METHODS OF USING THE SAMEJuly 2024April 2025Allow810NoNo
18788938CAPSID VARIANTS AND METHODS OF USING THE SAMEJuly 2024April 2025Allow810NoNo
18779961PREFUSION-STABILIZED HMPV F PROTEINSJuly 2024January 2025Allow610NoNo
18777836C-BASED SINGLE DOMAIN ANTIBODY FOR NEUTRALIZING RESPIRATORY SYNCYTIAL VIRUS AND APPLICATION THEREOFJuly 2024April 2025Allow910NoNo
18770056POLYNUCLEOTIDE MOLECULES USED FOR THE PREVENTION OR TREATMENT OF HPV INFECTION RELATED DISEASESJuly 2024March 2025Allow811YesNo
18762296BETACORONAVIRUS mRNA VACCINESJuly 2024October 2024Allow310YesNo
18762372BETACORONAVIRUS RNA VACCINESJuly 2024December 2024Allow510NoNo
18751599BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONSJune 2024December 2024Allow610YesNo
18749700COMPOSITIONS AND METHODS FOR AMPLIFYING, DETECTING OR QUANTIFYING HUMAN POLYOMAVIRUS BK VIRUSJune 2024April 2025Allow1001YesNo
18749697COMPOSITIONS AND METHODS FOR AMPLIFYING, DETECTING OR QUANTIFYING HUMAN POLYOMAVIRUS BK VIRUSJune 2024October 2025Allow1611NoNo
18743581SMALLPOX VACCINE FOR CANCER TREATMENTJune 2024January 2026Allow2021NoNo
18742851NOVEL PORCINE ROTAVIRUSJune 2024July 2025Abandon1410NoNo
18742986METHODS AND PRODUCTS FOR GENETIC ENGINEERINGJune 2024March 2025Allow910YesNo
18734010ADOPTIVE CELLULAR THERAPYJune 2024May 2025Allow1210NoNo
18734520MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITYJune 2024January 2025Allow800NoNo
18733214IMMUNOGENIC TRIMERSJune 2024December 2025Allow1920NoNo
18731059METHOD OF ASSESSING RISK OF PMLMay 2024April 2025Allow1110NoNo
18680137METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTORMay 2024March 2025Allow1010NoNo
18675059CHIKUNGUNYA VIRUS (CHIKV) VIRUS-LIKE PARTICLES (VLPS) COMPRISING THE C, E1, AND E2 STRUCTURAL PROTEINSMay 2024December 2024Allow700NoNo
18670296ONCOLYTIC VIRUS STRAINMay 2024December 2025Allow1911YesNo
18670452CONSERVED REGION T CELL VACCINES FOR CORONAVIRUS AND METHODS OF USEMay 2024March 2025Allow1000NoNo
18668571USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALSMay 2024March 2025Allow1000NoNo
18667247IMMUNOGENIC COMPOSITIONS AND USES THEREOFMay 2024July 2025Allow1410NoNo
18665920Compositions and Methods for Antigen Targeting to CD180May 2024March 2025Allow1010NoNo
18665250METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINESMay 2024September 2025Allow1611YesNo
18665309RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/PIV3 F PROTEIN AND USES THEREOFMay 2024January 2026Allow2010NoNo
18662554METHODS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A PROTEINMay 2024April 2025Allow1110NoNo
18662436CHIMERIC INFLUENZA VACCINESMay 2024July 2024Allow200NoNo
18660609PORCINE EPIDEMIC DIARRHEA VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROMMay 2024February 2025Allow900YesNo
18659530VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING THE SAMEMay 2024August 2025Abandon1510NoNo
18655777METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3May 2024October 2025Allow1820NoNo
18656531T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use ThereofMay 2024September 2025Abandon1710NoNo
18654557COMPOSITIONS FOR USE IN TREATMENT OF ACNEMay 2024August 2025Allow1520YesNo
18654901COXSACKIEVIRUS A6 STRAIN CVA6-KM-J33 AND USE THEREOFMay 2024September 2024Allow410NoNo
18651541USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTIONApril 2024July 2025Abandon1510NoNo
18649981METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENTApril 2024January 2025Allow810YesNo
18649467A549 HOST CELLS COMPRISING A RECOMBINANT ONCOLYTIC ADENOVIRUS WITH MODIFIED E1A CANCER-SPECIFIC PROMOTERApril 2024December 2024Allow800NoNo
18648190STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOFApril 2024December 2024Allow700NoNo
18645951METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18645961METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18645942METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTApril 2024October 2024Allow611NoNo
18644438ANTIBIOTIC FREE TREATMENT OF MASTITISApril 2024December 2024Allow811YesNo
18641205COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERYApril 2024February 2025Allow1010NoNo
18639558METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATIONApril 2024August 2025Abandon1610NoNo
18639598GROUP B ADENOVIRUS-CONTAINING FORMULATIONApril 2024March 2026Allow2321YesNo
18637070COMPOSITIONS TARGETING APOPTOSIS-ASSOCIATED SPECK-LIKE PROTEIN WITH CASPASE ACTIVATION AND RECRUITMENT DOMAIN (ASC) AND METHODS OF USEApril 2024September 2024Allow501NoNo
18635203TROPICAL DISEASE VACCINESApril 2024February 2026Abandon2201NoNo
18634012ADJUVANT AND VACCINE CONTAINING ADJUVANTApril 2024February 2026Abandon2221NoNo
18630437ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUSApril 2024March 2025Allow1110NoNo
17270341BINDING PROTEIN OF NS1 PROTEINApril 2024February 2025Allow4720NoNo
18629504Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024January 2025Allow920NoNo
18629466Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024March 2025Allow1110YesNo
18629579Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024February 2025Allow1110YesNo
18629097Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024January 2025Allow920NoNo
18624929Adenoviral VectorApril 2024March 2025Allow1210NoNo
18622330IMMUNOGENIC COMPOSITIONS AND USES THEREOFMarch 2024June 2025Allow1410NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1671.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
100
Examiner Affirmed
64
(64.0%)
Examiner Reversed
36
(36.0%)
Reversal Percentile
67.1%
Higher than average

What This Means

With a 36.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
464
Allowed After Appeal Filing
176
(37.9%)
Not Allowed After Appeal Filing
288
(62.1%)
Filing Benefit Percentile
80.7%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1671 - Prosecution Statistics Summary

Executive Summary

Art Unit 1671 is part of Group 1670 in Technology Center 1600. This art unit has examined 8,817 patent applications in our dataset, with an overall allowance rate of 81.5%. Applications typically reach final disposition in approximately 24 months.

Comparative Analysis

Art Unit 1671's allowance rate of 81.5% places it in the 70% percentile among all USPTO art units. This art unit has an above-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1671 receive an average of 1.54 office actions before reaching final disposition (in the 24% percentile). The median prosecution time is 24 months (in the 82% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.